MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer

DSpace Repository

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer

Author: Neven, Patrick; Johnston, Stephen R. D.; Toi, Masakazu; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A.; Koh, Han; Grischke, Eva-Maria; Conte, PierFranco; Lu, Yi; Haddad, Nadine; Hurt, Karla C.; Llombart-Cussac, Antonio; Sledge, George W.
Tübinger Autor(en):
Grischke, Eva-Maria
Published in: Clinical Cancer Research (2021), Bd. 27, H. 21, S. 5801-5809
Verlagsangabe: Philadelphia
Language: English
Full text: http://dx.doi.org/10.1158/1078-0432.CCR-20-4685
ISSN: 1078-0432
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)